Understanding the role of Bruton's tyrosine kinase (BTK) inhibitors in the treatment of hematological cancers

< Back

75 minutes Understanding the role of Bruton's tyrosine kinase (BTK) inhibitors in the treatment of hematological cancers

This publication is sponsored by :

BeiGene Canada

A question ?

Understanding the role of Bruton's tyrosine kinase (BTK) inhibitors in the treatment of hematological cancers

1.25 CEU*

Accreditation CCCEP expiry date: May 24, 2025
CCCEP: #1296-2024-3824-I-P

Publication date: June 15, 2024

Author(s):
Annick Dufour, B.Pharm, M.Sc.

Reviewer(s):
Justine Couturier, B.Pharm, M.Sc., Pharmacist, Centre intégré de cancérologie de Laval (CICL) and GMF Medicentre Chomedey
Emie Desruisseaux, Pharm.D., M.Sc.

Speaker(s):
Tina Crosbie, BSc. (Pharm), ACPR, RPh, Clinical Pharmacist, Hematology and Past President, Canadian Association of Pharmacy in Oncology (CAPhO)

Accreditations :
CCCEP: #1296-2024-3824-I-P

To view this activity, add it to your personal space.

Add the activity
to your account
and watch it

Pass the quiz
to obtain
your CEUs

Complete the
activity evaluation

Obtain your statement
of attendance

To discover without delay!

Other activities that might interest you!

Webinar

Basal Insulin Update: The Role of Basal Insulin in Type 2 Diabetes Management (Module 1)

30 minutes

Published September 11, 2024

0.50 CEU CCCEP accreditation

Webinar

After Cholesterol, Focusing on Triglycerides : What the Evidence Says (Module 1)

30 minutes

Published May 10, 2023

0.50 CEU CCCEP accreditation

Webinar

New in Basal Insulin: Weekly Insulin and its Practical Implications in Type II Diabetes

75 minutes

Published November 29, 2024

1.25 CEU CCCEP accreditation